COVID-19 Response

COVID-19 Response

Jazz is implementing a robust continuity plan in response to the COVID-19 pandemic in order to deliver on our purpose of transforming the lives of patients through innovation. Our focus at Jazz is to develop life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully, and to support our patient communities in their overall wellness. Especially during a time of uncertainty as we live through this global pandemic, Jazz remains dedicated to this purpose.

In responding to this pandemic, Jazz’s top priorities are the health and safety of our employees and patient access to our medications. We have established a response team that is continually monitoring this public health situation to address potential impact to our employees, our sites and our business.

Employee Health and Safety

With employee and community safety in mind, we have implemented new remote work measures for our employees, including restricting business travel and closing offices. Jazz is following World Health Organization (WHO) and Center for Disease Control (CDC) recommendations, as well as national or local guidelines around the world. We are focused on supporting employees through this challenging time and are providing resources and processes if an employee receives a positive COVID-19 test result.

Product Supply to our Patients

As we announced on March 31st, we are confident in our ability to supply our medicines to patients around the world and currently have ample supply to meet patient needs well into the future, with the exception of Erwinaze which continues to have supply disruption unrelated to COVID-19. Jazz is working closely with the our third-party manufacturers, distributors and other trusted partners to manage the supply chain activities and mitigate any potential disruptions to our product supply as a result of COVID-19. We will continue to monitor any changes in COVID-19 impact to our supply chain.

At Jazz, we are committed to doing our best to ensure our communities can continue to receive the life-changing, often live-saving medicines they need – but our efforts go further. People may need more support as we all navigate the COVID-19 pandemic together, which is why we have JazzCares and our other specific patient support programs. We know you may have questions and concerns about your medicines or your (or your loved ones’) overall health during this time. JazzCares has a Patient Support Hotline: 1-833-533-JAZZ (5299), with live operators available to support Monday – Friday, 8 AM to 8 PM EST.

We also are committed to being there for people living with serious disease and will provide tips and resources about how to stay healthy during this isolating and challenging time. Now, we need to support each other more than ever.

Supporting our Local Communities

Jazz is committed to supporting our local communities and patient-focused organizations in COVID-19 relief efforts. To support those individuals and families who need extra help during the COVID-19 pandemic, Jazz has made corporate donations to charitable organizations providing food and medical relief to our local communities in Italy, Philadelphia and the Santa Clara and San Mateo Counties in California. Jazz is also exploring ways to enable employees to give back, like allowing healthcare practitioners employed by Jazz to support local response efforts.

Jazz will continue to monitor the impact of the pandemic across our communities and regularly reevaluate global relief efforts. We are proud to do our part to further support our communities where we live and work.

The COVID-19 pandemic is an unprecedented moment in our history and is affecting each of us and the patient communities we serve across the world in different ways. Our thoughts are with all of those whose lives have been affected by COVID-19. Jazz is committed to providing essential medicines to patients around the world and protecting the health and safety of our employees.

We will get through this together.

Cautionary Notice. This page contains forward-looking statements, including, but not limited to, statements related to continuity plans in light of COVID-19 and availability of product supply and other statements that are not historical facts. These statements are based on Jazz Pharmaceuticals’ current plans, expectations and intentions and actual results could differ materially as a result of the uncertain scale and duration of the COVID-19 pandemic and resulting global economic and financial disruptions and other risks and uncertainties including those described from time to time under the caption “Risk Factors” in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K for the year ended December 31, 2019. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements.